AstraZeneca India was established in the year 1979 and is headquartered at Bengaluru. AstraZeneca Pharma India Limited (AZPIL) is the functioning company and covers manufacturing, sales and marketing activities of the company in India. It is listed in stock exchange and is a subsidiary of AstraZeneca Plc, UK. It has a workforce of over 1400 employees (approximately) across the country that is dedicated to bring life-changing medicines to patients through innovative Science and international brilliance in growth and commercialization. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. Rated as one of the supreme in South East Asia, AstraZeneca’s Indian manufacturing facility has an urbane production facility designed to meet the most stringent international standards, conforming to WHO cGMP (current Good Manufacturing Practices) norms. The facility is an ISO 14001 certified company and has a full-fledged surroundings supervision system in place.
PHARMA INDUSTRY IN INDIA
• India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK (approximately).
• Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms.
• Indian pharmaceutical sector is expected to grow to US$ 100 billion, while medical device market is expected to grow US$ 25 billion by 2025. Pharmaceuticals export from India stood at US$ 16.3 billion in FY20 (approximately).
• The Union Cabinet has given its nod for the amendment of existing Foreign Direct Investment (FDI) policy in the pharmaceutical sector in order to allow FDI up to 100% under the automatic route for manufacturing of medical devices subject to certain circumstances.
• Medicine spending in India is projected to grow significantly over the next five years, leading India to become one of the top 10 countries in terms of medicine expenditure.
• ‘Pharma Vision 2020’ by the Government’s Department of Pharmaceuticals aims to make India a major hub for end-to-end drug discovery.
COMPANY PERSPECTIVE AND REVIEW
• The company registered sales of 8,013 million with a growth of 17% achieving a total all-inclusive income of 673 million, during the financial year 2019-20 (approximately).
• The current year growth for the company comes from the concentrating therapeutic areas like Cardio-Metabolism, Oncology and Respiratory. Products supplied by the company have been classified as essential goods during the COVID-19 pandemic.
• The mechanized facility's of the company is currently sourcing 70% of energy through solar power which enables it to be more cost effective and considerably reduce carbon footprint.
• The 3 year CAGR growth of the company is 15% in revenue and 53 % in net profit (approximately). For the year ending March 2020 AstraZeneca Pharma has declared an equity dividend of 50.00% amounting to Rs 1 per share.
• Recently, AstraZeneca has been in the forefront in developing the Covid-19 vaccine for the world. After, WHO gave emergency use approval to its vaccine last year; it has been distributing the same to many developing countries of the world.
• The company has a good dividend track record and has constantly declared dividends for the last 5 years. The technical indicators of the company show good potential in the long run.